Shots:
- AbbVie and IGI Therapeutics, a subsidiary of Ichnos Glenmark Innovation, have entered into an exclusive licensing deal for ISB 2001, a drug targeting oncology & autoimmune diseases developed using IGI’s proprietary BEAT protein platform
- As per the deal, AbbVie will obtain exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan & Greater China in exchange for $700M upfront, ~$1.225B in development, regulatory, and commercial milestones, with net sales-based double-digit royalties, subject to regulatory clearance
- ISB 2001, a first-in-class tri-specific T-cell engager targeting BCMA, CD38, and CD3, is in Phase 1 for relapsed/refractory multiple myeloma
Ref: Abbvie | Image: Abbvie | Press Release
Related News:- AbbVie to Acquire Capstan Therapeutics for ~$2.1B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
